Learn about Adult Polycystic Kidney Disease (ADPKD), also known as Autosomal Dominant Polycystic Kidney Disease. This resource provides information on diagnosis, clinical documentation, and medical coding for ADPKD, including ICD-10 codes and SNOMED CT concepts relevant for healthcare professionals. Find details on symptoms, genetic testing, and management of polycystic kidney disease in adults.
Also known as
Cystic kidney disease
Congenital cystic kidney diseases, including polycystic kidney.
Diseases of the genitourinary system
Encompasses various kidney and urinary tract disorders.
Diseases of the circulatory system
Includes conditions affecting the heart and blood vessels, relevant to kidney complications.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the polycystic kidney disease acquired or genetic?
When to use each related code
| Description |
|---|
| Inherited disorder forming kidney cysts, leading to enlarged kidneys and kidney failure. |
| Acquired cystic kidney disease occurs in patients with long-term kidney disease, often on dialysis. |
| Medullary sponge kidney is a congenital disorder with cysts limited to collecting ducts in the kidneys. |
Missing or incorrect laterality coding for affected kidney(s) can impact reimbursement and data accuracy. ICD-10-CM coding guidelines require specifying laterality.
Failing to code associated manifestations like hypertension or renal failure with ADPKD undercodes severity and complexity, impacting risk adjustment.
Insufficient clinical documentation to support ADPKD diagnosis can lead to coding errors and denials. CDI can clarify documentation for accurate coding.
Q: How can I differentiate between simple cysts and polycystic kidney disease (PKD) in adult patients using imaging studies like ultrasound or CT scan?
A: Differentiating simple cysts from polycystic kidney disease (PKD) requires careful evaluation of imaging studies. While both present as fluid-filled structures in the kidneys, key differences exist. Simple cysts are typically solitary, smooth-walled, and anechoic on ultrasound or have low attenuation on CT. PKD, on the other hand, is characterized by multiple cysts in both kidneys, often varying in size. In autosomal dominant polycystic kidney disease (ADPKD), the most common type, the number and size of cysts increase with age. Imaging characteristics like enhanced through-transmission on ultrasound or sharply demarcated margins on CT are also suggestive of simple cysts. Furthermore, consider patient age and family history, as ADPKD has a strong hereditary component. Explore how genetic testing can aid in confirming a diagnosis of ADPKD. Consider implementing a standardized imaging protocol in your practice to ensure accurate and consistent assessment of cystic kidney disease. Learn more about the specific imaging criteria for diagnosing ADPKD according to established guidelines, such as those from the Kidney Disease Improving Global Outcomes (KDIGO) initiative.
Q: What are the latest evidence-based management strategies for adult polycystic kidney disease (ADPKD) progression, focusing on blood pressure control and renal function preservation?
A: Managing adult polycystic kidney disease (ADPKD) progression necessitates a multi-faceted approach focused on blood pressure control and renal function preservation. Tight blood pressure control, particularly with renin-angiotensin-aldosterone system (RAAS) inhibitors like angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme (ACE) inhibitors, is crucial in slowing disease progression. Studies have shown these agents can reduce the rate of kidney growth and preserve renal function in ADPKD patients. Beyond blood pressure control, addressing other modifiable risk factors, such as managing proteinuria, is essential. Emerging therapies, like tolvaptan, a vasopressin V2 receptor antagonist, have demonstrated efficacy in slowing kidney growth and decline in kidney function, especially in patients with rapidly progressing disease. Consider implementing a personalized management plan for each ADPKD patient based on their individual risk factors, disease stage, and comorbidities. Explore how incorporating lifestyle modifications, such as dietary adjustments and regular exercise, can complement pharmacological interventions. Learn more about the latest clinical trials and research on novel therapeutic targets for ADPKD.
Patient presents with concerns consistent with adult polycystic kidney disease (ADPKD), also known as autosomal dominant polycystic kidney disease. Clinical findings include bilateral flank pain, palpable renal masses, and hypertension. Family history is positive for ADPKD, supporting the suspected diagnosis. Ultrasound imaging reveals multiple renal cysts in both kidneys, meeting the diagnostic criteria for ADPKD. Differential diagnosis includes simple renal cysts, acquired cystic kidney disease, and multicystic dysplastic kidney. Assessment suggests chronic kidney disease (CKD) stage 2 based on estimated glomerular filtration rate (eGFR). Plan includes blood pressure management with an ACE inhibitor, pain management with NSAIDs (with caution due to renal function), genetic counseling referral, and monitoring for progression of CKD. Patient education provided on ADPKD, including lifestyle modifications, renal diet, and potential complications such as hypertension, renal failure, and cyst infections. Follow-up scheduled in 3 months to reassess renal function, blood pressure, and symptom management. ICD-10 code Q61.3 and SNOMED code 22200001 will be used for billing and coding.